Sponsors (21)
The bill aims to close the HPV diagnostic gap for men—potentially reducing HPV‑related cancers and improving surveillance and equity—but it will require upfront research, regulatory work, and resources that could increase costs, strain health system capacity, divert NIH funds, and risk uneven access for vulnerable populations.
Men — including high‑risk and underserved groups — would gain earlier, easier detection of HPV through development and approval of male diagnostics and standardized noninvasive tests, lowering their risk of HPV‑related cancers and reducing onward transmission.
Public‑health surveillance and prevention would improve because agencies would get actionable recommendations and interagency strategies to close the diagnostic gap for men, enabling earlier detection, better tracking of HPV, and potential reductions in cervical cancer among women.
Expanding screening and testing to include men would promote gender equity in cancer prevention and help reduce transmission‑related disparities that currently concentrate burden on women and some underserved populations.
If implementation and approval do not reach underserved communities, low‑income, uninsured, and racial‑ethnic‑minority groups could be left without access, worsening existing health inequities.
Developing and approving male HPV diagnostics and expanding testing could increase healthcare and regulatory costs (and demand FDA resources), potentially raising testing expenses for patients and taxpayers.
Expanding surveillance and testing without additional funding may strain clinics and laboratories, increasing workload and capacity pressures on hospitals and public‑health systems.
Based on analysis of 3 sections of legislative text.
Requires NIH to study and report on developing a standardized, noninvasive HPV diagnostic test for men, including pilot feasibility and interagency pathways to approval.
Official title: To direct the Director of the National Institutes of Health to conduct a study and submit to Congress a report on the development of a standardized, noninvasive test for HPV in men, and for other purposes.
Introduced May 20, 2026 by LaMonica McIver · Last progress May 20, 2026
Requires the NIH Director to lead a 24-month, interagency study on developing a standardized, noninvasive diagnostic test for HPV infection in men and to report findings and recommendations to Congress within 30 months. The work must assess current science, test approaches (oral, pharyngeal, anal, penile, urine), pilot feasibility in diverse and high‑risk populations, and interagency coordination toward regulatory approval, using NIH funds available for FY2026–FY2030. The bill also establishes an interagency working group including FDA, CDC, HRSA, and the National Academy of Medicine to support the study and implementation planning; the goal is to close gaps in surveillance, prevention, and early detection of HPV-related cancers among men and to improve overall cancer control and gender equity in HPV diagnosis and treatment.